1. Press Release
Theralase’s Innovative Anti-Cancer Technology Validated at Major International
Conferences
Toronto, Ontario – April 19, 2013 -- Theralase Technologies Inc. (TSX-V: TLT) announced today that its
innovative Photo Dynamic Compound (PDC) technology has been accepted for presentation at two
major international scientific conferences. Acceptance at these conferences validates the significance
of the technology and its efficacy in the destruction of cancer cells in research performed by
Theralase's internationally acclaimed scientists.
The efficacy of the anti-cancer Photo Dynamic Compound technology will be presented at LASER World
of Photonics conference in Munich, Germany on May 15, 2013.
The effective destruction of bacteria using Theralase’s light activated Photo Dynamic Compound
technology will be presented at Photonics North conference in Ottawa, Canada on June 3, 2013.
In further developments, Theralase’s Chief Scientific Officer, Dr. Arkady Mandel has been elected to
the Editorial Board of Photonics & Lasers in Medicine (PLM) journal and chosen as issue editor of PLM
for the Low Level Laser Therapy (LLLT) issue. PLM is an internationally peer-reviewed journal, which
publishes clinical and scientific studies concerned with the clinical and scientific application of lasers
and biophotonics in medicine for diagnostic and therapeutic purposes. PLM recently featured the
clinical success of Theralase’s pivotal randomized placebo controlled clinical trial entitled, “Laser
Therapy Applications for Osteoarthritis and Chronic Joint Pain.”
Roger Dumoulin-White, President and CEO of Theralase said, "I am pleased that Theralase’s scientific
and clinical research has been recognized and acclaimed by two of the finest international scientific
conferences and has been published in a peer reviewed medical journal. Theralase is committed to the
early commercialization of its patented light activated Photo Dynamic Compounds in the areas of anti-
cancer and anti-bacterial applications to generate substantial revenue increases for the Company. To
accelerate this process, we are actively looking to collaborate with strategic partners to further
develop our technologies and increase shareholder value. Theralase’s strong PDC pipeline has
scientifically proven that our PDC technology is capable of consistently producing cell kill levels of
100%, even at very low concentrations, across a wide range of cancers and bacteria. In fact, our PDCs
have been proven to be significantly more effective in destroying cancer cells and bacteria than
currently FDA approved Photo Dynamic Compounds.”
About Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented,
superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase
technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural
muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo
Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when
light activated by Theralase’s proprietary laser technology.

2. Press Release
For further information please visit www.theralase.com , regulatory filings may be viewed by visiting
www.sedar.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to
update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts
responsibility for the adequacy or accuracy of this release.
For More Information
Roger Dumoulin-White
President & CEO
416-699-LASE (5273) ext. 225
rwhite@theralase.com
Kristina Hachey
Chief Financial Officer
416-699-LASE (5273) ext. 224
khachey@theralase.com
Arkady Mandel
Chief Scientific Officer
416-699-LASE (5273) ext. 260
amandel@theralase.com
Greg Bewsh
Director of Investor Relations
416-699-LASE (5273) ext. 258
gbewsh@theralase.com